Preclinical investigations with human pancreatic ductal adenocarcinoma (PDAC) cells have shown that oncogenic KRAS mutations reprogram glutamine metabolism through an alternative pathway that fuels the tricarboxylic acid (TCA) cycle and promotes tumor growth [4,5]. This evidence concerns the gene KRAS and neoplasm.